GoKawiil
Tech News
A phase III trial of intismeran, a personalized cancer vaccine developed by Merck and Moderna, showed that melanoma patients who received it had longer recurrence-free survival than those given a placebo. The double-blind study of more than 1,100 participants builds on an earlier phase II trial with 157 patients and moves the vaccine closer to regulatory approval.
The FDA has cleared daraxonrasib, a new drug for pancreatic cancer, after a large clinical trial found patients on the treatment survived roughly twice as long as those receiving standard chemotherapy. The approval gives doctors a new option for a disease long known for poor treatment outcomes.
The FDA has approved Rasonque (daraxonrasib), a once-daily pill designed to block multiple mutated forms of the RAS protein that drive most pancreatic adenocarcinoma tumors. It is cleared for adults with metastatic disease who have already tried one systemic treatment or cannot tolerate combination chemotherapy, and the agency says it acted ahead of its original review timeline.
A court in Bayonne, France, ruled that a flight attendant's breast cancer was connected to occupational hazards from her career, citing cosmic radiation exposure at altitude alongside secondhand smoke and repeated night shifts as contributing carcinogenic factors. The ruling formally recognizes the illness as work-related.
MIT scientists created a new vaccine adjuvant made of mRNA encoding two genes that push immune cells into a more active state via specific signaling pathways. Delivered in lipid nanoparticles in mouse models of bladder, colon, lung and skin cancers, the adjuvant slowed or eliminated tumors even without a cancer-specific vaccine, and worked even better alongside one or with checkpoint inhibitor drugs.